Vital stats: Cargill’s Xtend brand sucromalt is a novel sweetener similar to sucrose and high fructose corn syrup, but with a slow carbohydrate release.
Study claim: Sucromalt may help attenuate the perceived decline in mental and physical energy and rise in mental and physical fatigue that can occur 4-5 hours after ingestion of a high GI beverage. Mental Energy State, Physical Energy State, and Physical Fatigue State results favored sucromalt compared to glucose, with significant differences emerging particularly after 4-5 hours (P < 0.050). A trend toward a delay in Mental Fatigue State was also observed with sucromalt compared to glucose (P < 0.100). Minimal differences in ratings of hunger and sleepiness were observed between the beverages.
Published:Dammann, KW, et al. Effects of consumption of sucromalt, a slowly digestible carbohydrate, on mental and physical energy questionnaire responses. Nutr Neurosci2013 Mar;16(2):83-95.
Abstract:In this double-blind, randomized, crossover study, subjects (n = 44 healthy adults) consumed a standardized dinner, and following an overnight fast, ingested 75g of either sucromalt or glucose in solution at 7:30 AM the next day. Subjects completed validated questionnaires that assessed mental and physical energy, and fatigue, hunger, and sleepiness at baseline and hourly until 12:30 PM for a total of five post-consumption time points. Within-subject differences adjusted for baseline for individual questions and composite scores (Mental Energy State, Mental Fatigue State, Physical Energy State, and Physical Fatigue State) were analyzed using repeated measures analysis of variance.
Potential applications:As a substitute for sucrose and HFCS in nutrition bars, beverages, ice cream and other dairy products, jams and jellies, puddings and gelatins.
More info: www.cargillfoods.com/na/en/ie/FunctionalFoods/sucromalt-sweetener/index.jsp
Natto Pharma's MenaQ7
Vital stats:NattoPharma’s MenaQ7 (menaquinone-7), a vitamin K2 supplement.
Study claim:The results from the three-year human study on MenaQ7® show for the first time in history that daily intake of 180 micrograms MenaQ7 may help postmenopausal women to prevent bone loss, and therefore may drastically delay development of osteoporosis. Whether these results can be extrapolated to other populations, e.g., children and men, needs further investigation.
Published: Knapenm M. H. J., et al, Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int2013 Mar 23. Epub ahead of print.
Abstract:In a three-year, double-blind, randomized, placebo-controlled study, 244 healthy postmenopausal women aged between 55 and 65 years received either placebo capsules or capsules containing 180mcg MK-7 per capsule. One capsule was taken daily either with breakfast or dinner during a period of 36 months. Participants came to the research site every year for measurements of body weight and height, blood sampling, and DXA measurements. All noticeable changes in health, dietary pattern, physical activity, and/or medication use were recorded.
MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip. Bone strength was also favorably affected by MK-7. MK-7 significantly decreased the loss in vertebral height of the lower thoracic region at the mid-site of the vertebrae. MK-7 supplements may help postmenopausal women to prevent bone loss.
Potential applications:Every multivitamin, including children’s multivitamins, should contain vitamin K2. Postmenopausal women may benefit from taking MK-7 supplements to prevent the age-related bone loss.
More info: [email protected]